The ATP6V1D antibody targets the ATP6V1D protein, a crucial subunit of the vacuolar-type H+-translocating ATPase (V-ATPase) complex. V-ATPase is a multi-subunit proton pump responsible for acidifying intracellular organelles (e.g., lysosomes, endosomes, Golgi) and regulating pH-dependent processes such as protein degradation, membrane trafficking, and ion homeostasis. The ATP6V1D subunit, encoded by the ATP6V1D gene, is part of the peripheral V1 domain, which catalyzes ATP hydrolysis to drive proton translocation across membranes.
Antibodies against ATP6V1D are widely used in research to investigate V-ATPase assembly, function, and localization in cellular physiology and disease. Dysregulation of V-ATPase is linked to cancer metastasis, neurodegenerative disorders, osteoporosis, and renal tubular acidosis. ATP6V1D-specific antibodies enable detection of protein expression levels via Western blotting, immunofluorescence, or immunohistochemistry, aiding studies on its role in pH regulation, organelle dysfunction, or drug targeting.
Recent studies highlight ATP6V1D's potential as a biomarker or therapeutic target, particularly in cancers where V-ATPase overexpression correlates with invasiveness and chemoresistance. These antibodies also help explore genetic mutations or post-translational modifications affecting V-ATPase activity in rare genetic disorders. Proper validation (e.g., knockout controls) ensures specificity, minimizing cross-reactivity with other V-ATPase subunits. Overall, ATP6V1D antibodies are vital tools for dissecting V-ATPase-related mechanisms in health and disease.